Genetic biomarkers, such as APC, KRAS, NRAS, BRAF, PIK3CA, PTEN, TP53, and NDST4, reveal critical molecular pathways involved in CRC progression and provide actionable targets for precision therapies. This evidence concerns the gene BRAF and colorectal carcinoma.